← Back to Search

Other

BMS-984923 for Alzheimer's Disease

Q: Are individuals aged 30 or above eligible to partake in this experiment?

This medical trial welcomes patients aged between 50 and 80 years old.

Q: Has the FDA sanctioned Dose Under Fed Condition as a viable treatment?

With limited data available for safety and efficacy assessments, Dose Under Fed Condition was given a rating of 1.

Q: Am I qualified to take part in this research experiment?

Eligibility criteria for this trial is a diagnosis of Alzheimer's as well as being between 50 and 80 years old. 12 participants will be accepted into the program.

Q: Is this experiment still recruiting participants?

Evidently, the clinical trial has stopped recruiting participants. As per its summary on clinicialtrials.gov, it was originally posted in October 2023 and last updated April 5th of that same year. Despite this, there are still over 500 medical studies actively searching for patients to enrol at present.

Phase 1

Waitlist Available

Led By Stephanie Post, MD

Research Sponsored by Allyx Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 14 days

Awards & highlights

Study Summary

This trial is researching a new medicine to treat Alzheimer's and possibly slow its progression.

Who is the study for?

This trial is for healthy older adults aged 50-80 without cognitive impairments, who can follow the study's procedures. Participants must not be pregnant or at risk of pregnancy. Exclusions include those with a BMI >38 kg/m2 or weight <50 kg, significant neurological diseases, major psychiatric disorders, unstable medical conditions, and those on medications that could affect drug processing.Check my eligibility

What is being tested?

The trial is testing BMS-984923, a new compound potentially modifying Alzheimer's disease progression. It aims to understand how food affects the drug's behavior in the body among healthy volunteers who represent an older adult population.See study design

What are the potential side effects?

As this is an early-stage trial for BMS-984923 in humans, specific side effects are not yet fully known but may include typical drug-related reactions such as digestive discomforts, headaches, dizziness or allergic responses.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 14 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~14 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Area Under the Curve from 0 to 24h (AUC 24h)

Maximum Plasma Concentration (Cmax)

Time of Cmax (Tmax)

Secondary outcome measures

Electrocardiogram - QT Interval

Incidence of Treatment Emergent Adverse Events (TEAE)

Safety Laboratory abnormalities

Trial Design

2Treatment groups

Active Control

Group I: Dose Under Fed ConditionActive Control1 Intervention

Investigational Drug is administered with a meal

Group II: Dose Under Fasted ConditionActive Control1 Intervention

Investigational Drug is administered after fasting

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Michael J. Fox Foundation for Parkinson's ResearchOTHER

112 Previous Clinical Trials

535,144 Total Patients Enrolled

Allyx TherapeuticsLead Sponsor

2 Previous Clinical Trials

68 Total Patients Enrolled

Stephanie Post, MDPrincipal InvestigatorPrincipal Investigator

1 Previous Clinical Trials

50 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals aged 30 or above eligible to partake in this experiment?

"This medical trial welcomes patients aged between 50 and 80 years old."

Answered by AI

Has the FDA sanctioned Dose Under Fed Condition as a viable treatment?

"With limited data available for safety and efficacy assessments, Dose Under Fed Condition was given a rating of 1."

Answered by AI

Am I qualified to take part in this research experiment?

"Eligibility criteria for this trial is a diagnosis of Alzheimer's as well as being between 50 and 80 years old. 12 participants will be accepted into the program."

Answered by AI

Is this experiment still recruiting participants?

"Evidently, the clinical trial has stopped recruiting participants. As per its summary on clinicialtrials.gov, it was originally posted in October 2023 and last updated April 5th of that same year. Despite this, there are still over 500 medical studies actively searching for patients to enrol at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers

2023. "Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05817643.